We are live on ! Find out more
AICPI

ABG Innovation Capital Partners III Portfolio holdings

AUM $64.5K
1-Year Est. Return 1.01%
This Fund
S&P 500
This Quarter Est. Return
-7.71%
1 Year Est. Return
+1.01%
3 Year Est. Return
+5.56%
5 Year Est. Return
-85.52%
10 Year Est. Return
–
AUM
$2.41M
AUM Growth
-$27.5M
Cap. Flow
-$27.2M
Cap. Flow %
-1,129.46%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$27.2M
2
WHWK
Whitehawk Therapeutics
WHWK
+$30

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WHWK
1
Whitehawk Therapeutics
WHWK
$209M
$783K 32.53%
26,666
-1
-0% -$30
GNCA
2
DELISTED
Genocea Biosciences, Inc.
GNCA
$720K 29.91%
375,000
– –
SYBX
3
DELISTED
Synlogic
SYBX
$628K 26.09%
13,727
– –
LUNG icon
4
Pulmonx
LUNG
$79.4M
$163K 6.77%
4,521
– –
ACGN
5
DELISTED
Aceragen Inc
ACGN
$58K 2.41%
3,312
– –
NBRV
6
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$55K 2.29%
1,834
– –
AVIR icon
7
Atea Pharmaceuticals
AVIR
$380M
– –
-1,265,631
Closed -$27.2M

Similar funds

FFVM
Founders Fund VI Management San Francisco, California $45.8K AUM 58.63% 1-Year Est. Return
SNN
Shen Neil Nanpeng $36.3K AUM 179.45% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
MI
Motiv8 Investments Port St. Lucie, Florida $183K AUM 15.06% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
NA
Newport Asia San Francisco, California $2.21M AUM
IVSFI
IA Venture Strategies Fund II New York $4.08M AUM 174.71% 1-Year Est. Return

ABG Innovation Capital Partners III's Q3 2021 Portfolio in Review

As of Q3 2021, ABG Innovation Capital Partners III held 7 positions worth $2.41M, down 92% from $29.9M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

ABG Innovation Capital Partners III withdrew a net $27.2M in Q3 2021, closing 1 position and reducing 1 holding. Its most notable exit was Atea Pharmaceuticals, an estimated $27.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • ABG Innovation Capital Partners III's biggest Q3 2021 reduction was Whitehawk Therapeutics, cutting an estimated $30.
  • ABG Innovation Capital Partners III fully exited Atea Pharmaceuticals in Q3 2021, selling an estimated $27.2M.
  • ABG Innovation Capital Partners III's ten largest holdings make up 100% of its $2.41M portfolio in Q3 2021.
  • ABG Innovation Capital Partners III opened 0 new positions and closed 1 in Q3 2021.
  • ABG Innovation Capital Partners III's portfolio value fell 92% quarter-over-quarter to $2.41M.

Based on ABG Innovation Capital Partners III's 13F filing for Q3 2021, filed 15 Nov 2021.